31 Mar 2023
Assets50.60
Total Income48.79
EBITDA4.23
Profit After Tax1.07
NET Worth8.05
Reserves and Surplus2.63
Total Borrowing26.24
At a glance
Updated 2026-09-10The shares listed at ₹108.00, a 10.20% move from the issue price. Neochem Bio is a SME IPO with an issue size of ₹44.97 crore, proposed for listing on NSE SME. The offer opens on 2nd Dec 2025 and closes on 4th Dec 2025. The issue structure includes a fresh issue of ₹42.69 crore. The current listing schedule points to 9th Dec 2025.
Issue details
Listing atNSE SME
Issue typeBook Build Issue
Issue size₹44.97 Cr
Fresh issue₹42.69 Cr
Face value₹10
Price band₹93.00–₹98.00
Allotment5th Dec 2025
Listing9th Dec 2025
Listing performance
Full performance ↗Issue price₹98.00
Listing price₹108.00
Current price—
Listing gain10.20%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹2.00
GMP / upper price2.04%
Est. listing₹100.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens2nd Dec 2025
Closes4th Dec 2025
Allotment5th Dec 2025
Refund8th Dec 2025
Demat8th Dec 2025
Listing9th Dec 2025
Subscription demand
Full bidding ↗QIB21.97×
sHNI11.88×
bHNI17.16×
NII / HNI17.16×
Retail9.42×
Total15.52×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 2400 | ₹235,200 |
Company
Incorporated2006
Use of proceeds
| Object | Amount |
|---|---|
| Funding the long-term working capital requirements of the Company | ₹23.90 Cr |
| Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company | ₹10.00 Cr |
| General Corporate Purposes | ₹6.44 Cr |
| Issue Expenses | ₹4.63 Cr |
| Total | ₹44.97 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue47.18₹ Cr · -45.2% vs prior year
EBITDA8.59₹ Cr · -34.5% vs prior year
PAT5.48₹ Cr · -29.3% vs prior year
Assets96.49₹ Cr · +22.3% vs prior year
Net Worth32.24₹ Cr · +63.2% vs prior year
Borrowing38.54₹ Cr · +8.2% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2024
Assets64.06
Total Income62.01
EBITDA5.99
Profit After Tax1.80
NET Worth12.00
Reserves and Surplus5.33
Total Borrowing33.32
31 Mar 2025
Assets78.89
Total Income86.15
EBITDA13.11
Profit After Tax7.75
NET Worth19.75
Reserves and Surplus13.08
Total Borrowing35.62
30 Sep 2025
Assets96.49
Total Income47.18
EBITDA8.59
Profit After Tax5.48
NET Worth32.24
Reserves and Surplus19.70
Total Borrowing38.54
KPIs
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 48.82% |
| ROCE | 41.67% |
| Debt / Equity | 1.80% |
| RoNW | 48.82% |
| PAT Margin | 9.00% |
| EBITDA Margin | 15.58% |
| Price to Book Value | 5.8 |
Valuation & shareholding
Pre-IPO EPS6.18
Post-IPO EPS6.41
Pre-IPO P/E15.85
Post-IPO P/E15.3
Promoter holding pre91.12%
Promoter holding post66.7%
Market cap₹167.78 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Neochem Bio Solutions IPO | — | 15.30 x | — | — |
| Shanti Inorganic IPO | — | 16.63 x | — | — |
| Devson Catalyst IPO | — | 12.81 x | — | — |
| Biopol Chemicals IPO | — | 14.58 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Funding the long-term working capital requirements of the Company | ₹23.90 Cr |
| Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the Company | ₹10.00 Cr |
| General Corporate Purposes | ₹6.44 Cr |
| Issue Expenses | ₹4.63 Cr |
| Total | ₹44.97 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- Vivro Financial Services Pvt.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-10.
IPO UPDATE ALERTS
Register for IPO Updates →Track Neochem Bio without missing an update
Register for subscription, GMP, allotment and listing notifications.